| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT04945824 Details | 2023-02-06 Interventional | 1 | 2 | Dexamethasone Healthy | inserter device did not perform as expected - | |||
| NCT04220125 Details | 2023-02-06 Interventional | 4 | 0 | Ketamine Midazolam Depressive Diso… | No enrollment - | |||
| NCT03614728 Details | 2023-02-06 Interventional | 1/2 | 30 | Azacitidine GSK-3326595 Leukemia Leukemia, Myelo… Leukemia, Myelo… Myelodysplastic… Preleukemia Neoplasms | Trial terminated due to internal review of clinical data in context of indication under
investigation - | |||
| NCT05135845 Details | 2023-02-03 Interventional | 2 | - | Spartalizumab Adenocarcinoma Gastric Adenoca… Oesophageal Ade… | Sponsor decision up DSMB advice due to unfavorable toxicity profile - | |||
| NCT04334174 Details | 2023-02-03 Interventional | 2 | 0 | Brentuximab Ved… Lymphoma Lymphoma, T-Cel… Lymphoma, T-Cel… T Cell Lymphoma | accrual not met - | |||
| NCT03523728 2017-004084-12 Details | 2023-02-03 Interventional | 2/3 | [1 Refs] | 478 | Venglustat Polycystic Kidn… Polycystic Kidn… | Interim analysis for futility of the Stage 1 of the EFC15392 study met the protocol specified
stopping rule based on the primary endpoint. EFC15392 study was stopped for futility based on
prespecified criteria and recommendation from DMC Following decision to discontinue EFC15392 based on the futility analysis, the two-steps analysis initially planned were not applicable, therefore only the final analysis of all safety endpoints (laboratory, vital sign, ECG, physical examination, BDI-II, and lens opacity) were performed on extended combined Stage 1 and Stage 2 safety population only. | ||
| NCT02513667 Details | 2023-02-03 Interventional | 2 | 14 | Ceritinib Adenocarcinoma Adenocarcinoma … ALK-positive No… | The study was terminated after UTSW was informed by Novartis that further support for the study
would not be provided - | |||
| NCT04650217 Details | 2023-02-02 Interventional | 4 | 1 | Carbidopa Carbidopa, levo… Levodopa Depressive Diso… | Study terminated by sponsor (NIMH) - | |||
| NCT03430791 Details | 2023-02-02 Interventional | 2 | 5 | Ipilimumab Nivolumab Glioblastoma Recurrence Recurrent Gliob… | Study Investigator/Sponsor decided to end enrollment earlier. Did not accrue the target number of participants needed to achieve target power and statistically reliable results. | |||
| NCT01309074 Details | 2023-02-02 Interventional | 4 | 0 | Pregabalin Sertraline Anxiety Disorde… Epilepsy Anxiety | No subjects could be enrolled and therefore we decided to withdraw/stop the study. - | |||
| NCT05179772 Details | 2023-02-01 Interventional | 2 | 0 | Olanzapine Opioid-Related … Opioid Use Diso… | NIDA has advised us to terminate this protocol due to the difficulties in finding appropriate
subjects. - | |||
| NCT03548246 Details | 2023-02-01 Interventional | 2 | 0 | Abiraterone Ace… Fludrocortisone Hydrocortisone Adrenal Hyperpl… Adrenocortical … Adrenogenital S… Hyperplasia Congenital Adre… | This study plan has halted and was withdrawn from the IRB. - | |||
| NCT03251417 Details | 2023-02-01 Interventional | 2 | 11 | Apatinib Irinotecan Carcinoma Carcinoma, Squa… Esophageal Squa… | Because PD-1 antibodies had been proved to be a standard second-line treatment in esophageal
cancer, the potential benefit of present intervention is under re-evaluation. - | |||
| NCT01433328 Details | 2023-02-01 Interventional | 4 | 4 | Lidocaine Pulmonary Arter… | Safety considerations - | |||
| NCT03876028 Details | 2023-01-31 Interventional | 1 | 10 | Ibrutinib Tisagenlecleuce… Lymphoma Lymphoma, B-Cel… Lymphoma, Large… Diffuse Large B… | Business reasons - | |||
| NCT03624985 Details | 2023-01-31 Interventional | 4 | 61 | Lidocaine Pain, Postopera… Opioid Use | Subjects had a high dropout rate. Of 61 consented, 24 did not participate. Reasons: Surgical
cancellations; changing procedure type after consent; and staffing issues. The dropout rate of
39% was considered a barrier to publication. - | |||
| NCT01048138 Details | 2023-01-31 Interventional | 3 | 123 | Biperiden Biperiden lacta… Brain Injuries Brain Injuries,… Traumatic Brain… | Recruitment and funding issues, together with the event of the SARS-CoV-2 pandemic prompted an
adjustment in the study design to stop enrollment at 123 patients. - | |||
| NCT00823342 2008-000733-21 Details | 2023-01-31 Interventional | 3 | - | Clevudine Tenofovir Hepatitis Hepatitis A Hepatitis B Hepatitis B, Ch… Hepatitis, Chro… Virus Diseases HBe Negative Ch… Hepatitis B Vir… | safety aspects - | |||
| NCT05601648 Details | 2023-01-30 Interventional | 2 | 0 | Psilocybin Anhedonia Depressive Diso… Depressive Diso… Major Depressiv… | Due to negative results in similar trials using 11C-UCB-J - | |||
| NCT05504486 Details | 2023-01-30 Interventional | 4 | 0 | Brexpiprazole Depression Depressive Diso… Depressive Diso… Major Depressiv… | Sponsor strategic decision - |